Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Dorgali MV, Longo A, Vass C, Shields G, Harrison R, Boeri M. Exploring Antimicrobial Resistance (AMR) from a societal perspective: preferences and welfare impacts in the United Kingdom. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
D'Souza VK, Alderson D. Early access and targeted supply considerations in emerging markets. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2):S656. doi: 10.1016/j.jval.2020.08.1524
Turner AJ, Vass C. Matching techniques in stated preferences for health. Presented at the Virtual ISPOR Europe 2020 Conference; November 9, 2020. [abstract] Value Health. 2020 Dec; 23(Supplement 2):S758. doi: 10.1016/j.jval.2020.08.2086
Stevenson A, Gildea L. A Medtech roadmap: new routes to market access in the UK NHS. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2):S576.
Vass C, Rigby D, Payne K. Watching ME watching you: understanding the effect of experimental setting on stated preferences. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Noon K, Costello J, Krieger T, Rothwell B, Pearson I. Utility weight considerations in NICE immune checkpoint inhibitor oncology appraisals. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039
Shah SN, Hepp Z, Martin S, Harris N, Morgans A. Qualitative analysis of pain in patients with locally advanced or metastatic urothelial cancer. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Herring W, Gould I, Haines P, Thompson R, Pemberton-Ross P. Predicted delays in dementia onset for an innovative therapy acting on beta-amyloid in patients with mild cognitive impairment due to Alzheimer's disease. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Purser M, Gallagher M, Mladsi D, Weber JM, Andemariam B, Kaye JA, Chawla A. Evaluation of published models in sickle cell disease against key criteria for an economic model for a potentially curative one-time treatment. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2). doi: 10.1016/j.jval.2020.08.098
Manga N. Applying a normal distribution to costs in probabilistic sensitivity analysis - NOT necessarily a negative outcome. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Molnar D, D'Souza V, Martin A. How the disease progression is captured in COPD models? A systematic literature review of disease and economic models. Poster presented at the 2020 Virtual ISPOR Europe; December 2020. [abstract] Value Health. 2020 Nov; 23(S2):S729-30. doi: 10.1016/j.jval.2020.08.1947
Bassali J, Gould I, Mladsi D, Kaye JA, Shah J, Mehta J. A US budget impact model for selinexor in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S33.
Myers K, Klein K, Mansfield C, Poulos C. A review of the use of comprehension questions in health preference studies. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S319-20. doi: 10.1016/j.jval.2020.04.1189
VanderPluym JH, Ramirez-Campos V, Cortez A, Cohen J, Gandhi S, Lewis S, Sweeney C, DeMuro C, Lipton R. Patient-reported outcomes to assess symptoms and effects across all 5 phases of migraine. Poster presented at the 2020 ISPOR Conference (Conference cancelled); May 2020. [abstract] Value Health. 2020 May; 23(Supplement 1):S280.
Vass C, Boeri M, Poulos C. Association between access device and stated preferences for health care. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1;. doi: 10.1016/j.jval.2020.04.1183
Poulos C, Hauber B, Mirzaei F, Dilley A, DeMuro C, Fillit HM. A study of preferences for disease-modifying treatments for Alzheimer's Disease. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S278. doi: 10.1016/j.jval.2020.04.991
Poulos C, Vass C, Klein K, Boeri M. Scope tests in health care discrete choice experiments. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S320. doi: 10.1016/j.jval.2020.04.094
Reynolds M, Odom D, Richardson D, Hollis KA, Zhan L, Mitra D, McRoy L, Bowles S. Benefits and challenges of mobile health applications in prospective studies: learnings from the Madeline Study and literature. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S71-2. doi: 10.1016/j.jval.2020.04.1183
Castro C, Mordin M, Islam Z, Tu N, Hackshaw MD, Salas M. A review of non-disease specific health-related quality of life measures with reliability and validity evidence in patients with breast cancer. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S81.
Saretsky T, Finelli L, Phillips M, DeMuro C, Lewis S, Norquist J, Monto A, Martin ET, Osborne RH. Measuring Respiratory Syncytial Virus (RSV) symptom intensity and impact in adults: content validity assessment of a Patient-Reported Outcome (PRO) measure: the RSV Infection Intensity and Impact Questionnaire (RSV-IIIQ). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Supplement 1):S360. doi: 10.1016/j.jval.2020.04.1380
Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen S. Impact of neurofibromatosis type 1 and plexiform neurofibromas on patient-reported health-related quality of life. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S344. doi: 10.1016/j.jval.2020.04.371
Meyers J, Hoog M, Mody R, Yu M, Hasenour C, Davis KL. Burden of cardiovascular disease and cardiovascular (CV) risk in patients with Type 2 diabetes mellitus (T2DM): an analysis of a US health insurance database. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S115. doi: 10.1016/j.jval.2020.04.371
Banjara B, Willke R, Guerino J, Ngorsuraches S. ISPOR top 10 HEOR trends: results from a best-worst scaling survey. Poster presented at the 2020 ISPOR Virtual Conference; May 16, 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S313. doi: 10.1016/j.jval.2020.04.1155
Banjara B, Kavookjian J. Interventions including motivational interviewing in adolescents with asthma: a systematic review. Poster presented at the 2020 ISPOR Virtual Conference; May 16, 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S349. doi: 10.1016/j.jval.2020.04.1331
Mansfield C, Boeri M, Coulter J, Baranowski E, Sparks S, Hamed A. Preferences for genetic tests: trading off speed of diagnosis, availability of treatment, and cost. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S345. doi: 10.1016/j.jval.2020.04.094
Filonenko A, Purser M, Mader G, Graham J. Impact of increased utilization of long-acting reversable contraceptive methods among young women on cost and unintended pregnancies (UP) in the United States (US). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S153. doi: 10.1016/j.jval.2020.04.371
Parikh RC, Niyazov A, Esterberg E, Arondekar B, Hitchens A, Shahied Arruda L, Obeid E. Real-world patient demographics, treatment patterns and healthcare resource utilization (HRU) among Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced Breast Cancer (ABC) patients with BRCA1/2 Mutations (BRCA1/2MUT). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S79. doi: 10.1016/j.jval.2020.04.094
Zhang Y, Herring W. The impact of alternative weighting methodologies on cross-indication value-based pricing estimates. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S289. doi: 10.1016/j.jval.2020.04.094
Sutphin J, DiSantostefano R, Leach CA, Hauber B, Mansfield C. Preferences, optimism, and numeracy: an exploration into the use of psychological patient-reported outcome instruments in a preference survey. Presented at the 2020 ISPOR Virtual Conference; May 19, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S328. doi: 10.1016/j.jval.2020.04.094
Sutphin J, Mansfield C, DiSantostefano R, Klein K, Boeri M. Getting the most out of latent-class analysis in modeling preferences for an interception treatment in Type 1 diabetes. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S125. doi: 10.1016/j.jval.2020.04.371
Gnanasakthy A, Barrett A, D'Alessio D, Norcross L. Review of patient and clinician global assessments in PRO labeling (2017-2019). Poster presented at the ISPOR Virtual 2020 Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S299. doi: 10.1016/j.jval.2020.04.094
Thach A, Sutphin J, Coulter J, Mansfield C. Preferences for on-demand treatments for Parkinson's disease–related "OFF" episodes: a discrete-choice experiment. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S325. doi: 10.1016/j.jval.2020.04.094
La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371
Yi Z, Mauskopf J, Herring W, Graham J. Challenges in estimating eligible population size in budget-impact analyses for new health care technologies. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S288. doi: 10.1016/j.jval.2020.04.371
Pearce AM, Mulhern BJ, Watson V, Viney RC. How are debriefing questions used in health discrete choice experiments? An online survey. Value Health. 2020 Mar;23(3):289-93. doi: 10.1016/j.jval.2019.10.001
Reed SD, McLeod L. Moving beyond the tip of the iceberg to incorporate patients' perspectives and outcomes in the medical device regulatory process. Value Health. 2020 Mar;23(3):298-9. doi: 10.1016/j.jval.2020.01.008
Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T. Cost-effectiveness of multigene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. Value Health. 2020 Jan 1;23(1):61-73. doi: 10.1016/j.jval.2019.08.002